About Alzamend Neuro, Inc.


What is Alzheimer's disease?

Alzamend Neuro is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Far too many individuals – patients and caregivers – suffer from the burden created by these devastating diseases. Our primary target, Alzheimer’s disease, was among the most-feared diseases (second only to cancer) among Americans, according to a 2011 survey by the Harvard School of Public Health. Alzheimer’s is also the sixth leading cause of death in the United States according to a 2020 Alzheimer’s Disease Facts and Figures report by the Alzheimer’s Association.


  • The number of Americans projected to be living with Alzheimer’s disease by the year 2050

  • The number of Americans projected currently living with Alzheimer’s disease in 2019

  • The estimate how often someone in the United States develops Alzheimer’s disease

  • Leading cause of death in the U.S.

  • The estimated number of seniors that will die with Alzheimer’s disease or other dementia by 2050

  • Leading cause of death for Americans age 65 and older & Leading cause of disability and poor health for Americans

  • The estimated cost in 2019 of Alzheimer’s disease to the United States.

  • The estimated value of unpaid care to Alzheimer’s patients by their caregivers including family and friends

  • The estimated cost of by 2050 of Alzheimer’s disease to the United States if no treatment or cure is found

  • The estimated number of Americans age 65 and over that are afflicted in 2019 with Alzheimer’s disease

  • Are 2 ½ times more likely than men to develop Alzheimer’s disease in the United States

  • Estimated number of Americans that will have Alzheimer’s disease or other form of dementia by 2050 if a treatment or cure is not found